2025 · 3rd Quarter (July 1 - Sep 30)

BRIDGEBIO PHARMA, INC.

Filed by BRIDGEBIO PHARMA, INC..

Open official filing

Source-reported fields

Filing overview

Type: 3rd Quarter - Report
Posted: Oct 20, 2025
Income: Not reported
Expenses: $270,000.00
Registrant: BRIDGEBIO PHARMA, INC.
Client: BRIDGEBIO PHARMA, INC.
Filing UUID: f894b943-8466-49e3-abf2-5571af53118b
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Camerons Law - H.R. 1414 Tax Provisions in H.R. 1 - One Big Beautiful Bill Act - R&D tax credit, bonus depreciation, interest deduction Provisions related to PBM Reform in H.R. 1 - One Big Beautiful Bill Act PBM Reform Act - H.R. 4317 ORPHAN Cures Act - included in H.R. 1 - One Big Beautiful Bill Act Orphan drug policies Scientific EXPERT Act of 2025 - H.R. 1532; S. 822

Literal federal measure citations: H.R. 1262, S 932, H.R. 1414, H.R. 1, H.R. 1, H.R. 4317, H.R. 1, H.R. 1532, S. 822

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.